Ovid Therapeutics (NASDAQ:OVID – Get Free Report)’s share price dropped 6.1% on Tuesday following a weaker than expected earnings announcement. The stock traded as low as $2.65 and last traded at $2.6750. Approximately 350,608 shares traded hands during trading, a decline of 85% from the average session volume of 2,305,716 shares. The stock had previously closed at $2.85.
The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02).
Analyst Ratings Changes
Several research firms recently commented on OVID. Roth Capital reiterated a “buy” rating and issued a $8.00 price objective on shares of Ovid Therapeutics in a report on Thursday, September 3rd. UBS Group reissued a “buy” rating on shares of Ovid Therapeutics in a research report on Friday, September 11th. Wolfe Research began coverage on shares of Ovid Therapeutics in a research note on Thursday, October 15th. They set an “outperform” rating and a $5.00 target price on the stock. Wall Street Zen raised shares of Ovid Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Guggenheim initiated coverage on shares of Ovid Therapeutics in a research note on Tuesday, October 6th. They issued a “buy” rating and a $7.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $6.00.
Hedge Funds Weigh In On Ovid Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of OVID. Jupiter Topco LLC bought a new stake in shares of Ovid Therapeutics in the second quarter worth $55,898,000. BlackRock Inc. purchased a new stake in Ovid Therapeutics during the second quarter valued at $29,115,000. Janus Henderson Group PLC bought a new position in Ovid Therapeutics in the first quarter valued at about $23,732,000. ADAR1 Capital Management LLC bought a new position in Ovid Therapeutics in the second quarter valued at about $19,953,000. Finally, Braidwell LP bought a new position in Ovid Therapeutics in the second quarter valued at about $15,923,000. 72.24% of the stock is owned by institutional investors.
Ovid Therapeutics Stock Performance
The company has a debt-to-equity ratio of 0.05, a current ratio of 12.39 and a quick ratio of 12.39. The firm has a 50-day simple moving average of $2.52 and a 200-day simple moving average of $2.39.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.
Further Reading
- Five stocks we like better than Ovid Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
